Add Yahoo as a preferred source to see more of our stories on Google. Michele Tafoya reacts to the latest assassination attempt on Donald Trump's life. She reflects on the Minnesota politician who was ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20260507422734/en/ The articles, information, and content displayed on this webpage ...

Michele Tafoya reacts to the latest assassination attempt on Donald Trump's life. She reflects on the Minnesota politician who was killed in their home & calls the current scene of the political ...

The report, required under Ohio’s Collin’s Law, outlines hazing violations involving fraternities, club sports and other student groups over the past five years. The report, required under Ohio’s ...

EQT Corporation remains a compelling buy after a recent selloff, with valuation still cheap and upside potential intact. Q1 2026 revenue surged 94.2% YoY to $3.38B, driven by premium price ...

Technology megacaps have pushed benchmark indexes to new records this month while the rest of the market is lagging behind. Traders can be forgiven for feeling like they’ve seen this movie before.

Michele Tafoya Thinks Mike Tomlin Will Be A Star On NBC | Don't @ Me w/Dan Dakich After spending many years with NBC, Michele Tafoya believes Mike Tomlin will be a star for the network this year after ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20260506329974/en/ The articles, information, and content displayed on this webpage ...

Reported positive results from aleniglipron Phase 2 ACCESS II study with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs at the 44-week time point and potentially ...

Definium Therapeutics, Inc. (“Definium” or the “Company”) (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying ...

- Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation ...